• • Company Profile
  • Executive Management
  • Board of Directors
  • Scientific Advisory Board
  • NexMed USA
  • TOTECT
• • NexACT®
  • DDAIP.HCl Properties
  • DDAIP.HCl Molecular Interactions
  • DDAIP: Mechanism of Action
  • NexACT® Diagram
  • Publications
• • Sexual Dysfunction
  • Oncology
  • Autoimmune/Anti-Inflammatory/Pain
  • Anti-Infectives & Cosmeceuticals
  • Metabolic Diseases
  • TOTECT
• • Stock Quotation
  • Interactive Chart
  • Fact Sheet
  • SEC Filings
  • SEC Filings - XBRL Content
  • Corporate Governance
  • Corporate Presentation
  • Social Media
• • Media & Events
  • Press Releases

Vitaros^® (topical alprostadil and DDAIP for the treatment of Erectile Dysfunction: approved in Canada, previously filed in US, and to be filed in Europe and MENA 2011 Q2)

Vitaros^® offers rapid onset with significant efficacy, tolerability and a favorable safety profile, including patients with compromised cardiovascular system such as diabetics or patients not responding to Viagra after a prostatectomy.

Phosphodiesterase inhibitors are effective in Erectile Dysfunction but can cause serious cardiovascular safety issues as well as significant side effects such as headache, muscle ache and impaired hearing and vision. Availability of a safer and effective treatment would address an unmet medical need. Apricus Bio's alprostadil topical cream Vitaros^® in combination with the NexACT^® proprietary permeation enhancer (DDAIP.HCL) has been designed to provide a rapid onset with significant efficacy, tolerability and a favorable safety profile.

Vitaros^® has been studied in over 3,300 patients including difficult to treat populations (diabetes, cardiac issues, sildenafil failures, prostatectomies, patients on nitrates and alpha blockers.) Vitaros^® demonstrates clinical efficacy and an excellent safety profile versus currently approved oral medication. Vitaros^® is approved in Canada .The NDA was filed in the U.S. Marketing authorization for Vitaros^® is scheduled to be filed in Europe, and certain Gulf and Middle Eastern countries during the 2011. Apricus Bio is seeking ex-US partners, excluding Asia, Australia and New Zealand.